Complete Conference Coverage Archive

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

mCRPC: Full-length AR Copy Number Prognostic for Outcomes

mCRPC: Full-length AR Copy Number Prognostic for Outcomes

Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.

Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible

Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible

A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.

Novel Mutated Genes, Pathways in Prostate Cancer Identified

Novel Mutated Genes, Pathways in Prostate Cancer Identified

Researchers identified nearly 80 significantly mutated genes in prostate cancer, including many novel genes and pathways.

Decipher Genomic Classifier Prognostic for Metastasis, PCa-specific Mortality

Decipher Genomic Classifier Prognostic for Metastasis, PCa-specific Mortality

The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Highest Genetic Risk Group Has 5-fold Higher Risk of Prostate Cancer

Highest Genetic Risk Group Has 5-fold Higher Risk of Prostate Cancer

The risk for developing prostate cancer is more than 5 times higher for men in the top 1% of the genetic risk score group.

Clinicians Address Barriers to Progress for Bladder Cancer

Clinicians Address Barriers to Progress for Bladder Cancer

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.

Impact of Early Immunotherapy Discontinuation in mRCC

Impact of Early Immunotherapy Discontinuation in mRCC

Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.

Targeting AR Mutations Promising In Prostate Cancer

Targeting AR Mutations Promising In Prostate Cancer

A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.

Nearly Half of Partners of Young Breast Cancer Survivors Report Anxiety

Nearly Half of Partners of Young Breast Cancer Survivors Report Anxiety

About 4 in 10 partners of young breast cancer survivors experience anxiety.

Exercise Reduction After Cancer Diagnosis: Factors and Consequences

Exercise Reduction After Cancer Diagnosis: Factors and Consequences

Three-quarters of patients diagnosed with cancer report decreased physical activity.

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.

Regorafenib Improves Overall Survival in Liver Cancer

Regorafenib Improves Overall Survival in Liver Cancer

Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.

Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

Phase 2 trials of investigational agents for pancreatic cancer treatment do not usually progress to phase 3.

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.

Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer

Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer

Salvage therapy with nivolumab was efficacious among patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) cancer.

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.

PET Scans Inform, Improve Treatment in Esophageal Cancer

PET Scans Inform, Improve Treatment in Esophageal Cancer

Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.

Physical Activity Associated With Improved PFS, OS in Advanced CRC

Physical Activity Associated With Improved PFS, OS in Advanced CRC

Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.

FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer

FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer

Despite differences in the safety profiles and rates of adverse events, both FOLFIRI and XELIRI were safe and well-tolerated as second-line therapy.

Watch-and-Wait Safe for Patients With Rectal Cancer

Watch-and-Wait Safe for Patients With Rectal Cancer

Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.

Surgical Palliation for Gastric Outlet Obstruction

Surgical Palliation for Gastric Outlet Obstruction

Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.

Nintedanib Improves PFS in mCRC Regardless of Prior Regorafenib Treatment

Nintedanib Improves PFS in mCRC Regardless of Prior Regorafenib Treatment

Treatment with nintedanib significantly improved progression-free survival among heavily pretreated patients with metastatic colorectal cancer (mCRC).

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Three cycles of epirubicin plus cyclophosphamide (EC) followed by docetaxel (EC-D) offered no survival benefits.

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Findings from a preclinical study of PI3K inhibitor taselisib's mechanism of action in mutant cell line and breast cancer xenograft models surprised researchers.

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Used alongside clinical variables, molecular prognostic signatures can identify postmenopausal women with ER+, HER2-negative breast cancer.

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA1 and BRCA2 mutation status predicts PFS in carboplatin-treated women with recurrent or metastatic triple-negative breast cancer (TNBC).

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

An orally-available formulation of proteolysis-targeting chimera (PROTAC) successfully degraded and reduced levels of estrogen-receptor alpha (ERα) protein.

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

Cancer drug prices will probably continue their steady climb.

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase inhibitor (AI) therapy is associated with endothelial dysfunction, a predictor of cardiovascular disease.

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

A biological risk profile can identify patients with ductal carcinoma in situ (DCIS) who are at high risk of recurrence and might benefit from radiotherapy.

Exercise and Gene Expression in Breast Cancer

Exercise and Gene Expression in Breast Cancer

Physical exercise might modulate the upregulation of immune and inflammatory-pathways involved in breast cancer.

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Subpopulations of tumor cells can form microanatomic associations with endothelial cells and macrophages.

Ki67 Suppression With Abemaciclib in Breast Cancer

Ki67 Suppression With Abemaciclib in Breast Cancer

Neoadjuvant therapy with the investigational oral CDK 4/6 inhibitor abemaciclib as monotherapy and with anastrozole reduced Ki67 levels.

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Adding the PI3K inhibitor buparlisib to fulvestrant endocrine therapy improves progression-free survival (PFS).

A Glimpse of ASH

A Glimpse of ASH

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating tumor microRNA signatures might discriminate between neoadjuvant chemotherapy-responsive and -unresponsive HER2+ breast cancers.

Complications of Post-mastectomy Irradiation

Complications of Post-mastectomy Irradiation

Post-mastectomy radiotherapy is associated with increased rates of complications like hematoma, infection, and reduced patient-reported satisfaction.

Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes

Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes

Circulating tumor cell (CTC) counts prior to neoadjuvant chemotherapy for early-stage breast cancer predict survival.

Aromatase Inhibitors in HR+, HER2+ Breast Cancer

Aromatase Inhibitors in HR+, HER2+ Breast Cancer

Pathologic complete response (pCR) rates in hormone receptor (HR)-positive, HER2-positive breast cancer were unchanged.

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.

BRCA Status Does Not Predict Survival for Young Patients With Breast Cancer

BRCA Status Does Not Predict Survival for Young Patients With Breast Cancer

BRCA1/2 mutation status does not predict survival among young patients.

Plasma Tumor DNA in Breast Oncology

Plasma Tumor DNA in Breast Oncology

Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).

Can Studying Tumor Ecology Reveal New Paths to Treatment?

Can Studying Tumor Ecology Reveal New Paths to Treatment?

Emerging research suggests that tumor development involves much more than mutant clones.

More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice

More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice

Circulating free tumor DNA techniques might improve the ability to match tumor mutations to genotype-matched targeted therapies.

Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk

Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk

BARD1, RAD51D, and MSH6 gene variants increase breast cancer risk.

Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

Higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS).

Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

Gene mutation status is prognostic for postmenopausal women with early-stage estrogen receptor-positive (ER+) breast cancer.

Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

Adding veliparib to carboplatin and paclitaxel for patients with advanced BRCA mutation-associated breast cancer is safe but did not improve survival.

The Challenges of Treating Triple-negative Breast Cancer

The Challenges of Treating Triple-negative Breast Cancer

A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).

Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival

Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival

Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.

No Breast Cancer Survival Benefit for Extending Adjuvant Letrozole Therapy to 5 Years

No Breast Cancer Survival Benefit for Extending Adjuvant Letrozole Therapy to 5 Years

Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.

Promising Options Emerging for Treating Metastatic ER+ Breast Cancer

Promising Options Emerging for Treating Metastatic ER+ Breast Cancer

Integration of newer targeted agents into combination therapies will necessitate the development of predictive biomarkers.

Everolimus Improves Fulvestrant Benefits in AI-Resistant Metastatic Breast Cancer

Everolimus Improves Fulvestrant Benefits in AI-Resistant Metastatic Breast Cancer

Adding everolimus to fulvestrant improves progression-free survival (PFS) among postmenopausal women.

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.

Tumor, Node, and Metastasis Classification: 8th Edition Changes

Tumor, Node, and Metastasis Classification: 8th Edition Changes

The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.

The Current State of HER2+ Breast Cancer Management

The Current State of HER2+ Breast Cancer Management

Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.

International Cooperation Vital for Preventing Lung Cancer

International Cooperation Vital for Preventing Lung Cancer

Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.

Treating Older Patients With Breast Cancer: Still a Challenge

Treating Older Patients With Breast Cancer: Still a Challenge

Lack of research data and failure to consider patients' functional age affects how older adults with breast cancer are managed.

Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML

Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML

Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.

Nilotinib Discontinuation Following Deep Molecular Response

Nilotinib Discontinuation Following Deep Molecular Response

Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.

Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer

Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer

Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.

Cabozantinib Safe and Effective in RET-rearranged Lung Cancer

Cabozantinib Safe and Effective in RET-rearranged Lung Cancer

Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.

Radiotherapy Doses Evaluated in NSCLC

Radiotherapy Doses Evaluated in NSCLC

A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.

Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.

Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.

TKI Cessation Appears Feasible, Safe in Patients With CML

TKI Cessation Appears Feasible, Safe in Patients With CML

Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).

No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML

No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML

There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease

CML-CP: Second TKI Discontinuation Safe and Successful

CML-CP: Second TKI Discontinuation Safe and Successful

Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.

ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia

ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia

All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.

Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP

Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP

Generic formulations of imatinib appear to be non-inferior to Novartis's Gleevec brand formulation with respect to clinical efficacy and tolerability.

Serum Free Light Chain Responses Better for Predicting Clinical Outcomes

Serum Free Light Chain Responses Better for Predicting Clinical Outcomes

Serum free light chain measurements correlate more closely with clinical outcomes than urine assessments in patients with light chain multiple myeloma.

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.

Lower Intensity Intensification Therapy in Childhood ALL

Lower Intensity Intensification Therapy in Childhood ALL

Pediatric patients with acute lymphoblastic lymphoma (ALL) at standard risk for relapse do not benefit from lower-intensity, delayed intensification therapy.

Brigatinib Shows Promise in ALK-positive NSCLC With Brain Metastases

Brigatinib Shows Promise in ALK-positive NSCLC With Brain Metastases

Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.

Concurrent Chemo-radiotherapy Viable for Elderly Patients With SCLC

Concurrent Chemo-radiotherapy Viable for Elderly Patients With SCLC

A high percentage of patients with limited-stage small cell lung cancer (SCLC) are elderly, but there is a lack of data concerning the efficacy and safety.

NSCLC Survival Associated With Institutional Differences in Quality of Care

NSCLC Survival Associated With Institutional Differences in Quality of Care

Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).

Researchers Find Modest Success in Tobacco Cessation Program

Researchers Find Modest Success in Tobacco Cessation Program

Researchers described "modest success" in a systematic multi-step clinical program to improve tobacco practices.

Genetic Alterations in NSCLC May Indicate Improved Response to Veliparib

Genetic Alterations in NSCLC May Indicate Improved Response to Veliparib

Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.

New Prediction Model Could Guide Shared Decision Making in NSCLC

New Prediction Model Could Guide Shared Decision Making in NSCLC

A novel risk-prediction model can identify patients at an increased risk of mortality following surgical treatment.

New Biomarker Identified for Malignant Pleural Mesothelioma

New Biomarker Identified for Malignant Pleural Mesothelioma

Researchers discussed efforts to demonstrate that fibroblast growth factor 18 (FGF18) is overexpressed in malignant pleural mesothelioma (MPM) tissues and cell models.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters